Targeted radioactive implants combined with chemotherapy are transforming inoperable pancreatic cancer into surgical ...
Hosted on MSN
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...
Targeted treatments, including antibody-drug conjugates and immunotherapy agents, are now standard of care for breast cancer, but there are limited data on the safety of combining these newer agents ...
Ben Newton, GE HealthCare’s global head of oncology, said the partnership will shift radiation therapy from a ...
177Lu-PSMA-I&T therapy improved radiographic progression-free survival in metastatic castration-resistant prostate cancer patients. The ECLIPSE trial compared 177Lu-PSMA-I&T with hormone therapy, ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
GE HealthCare (Nasdaq: GEHC) announced today that it entered into a new collaboration with Mayo Clinic centered around cancer ...
Using targeted radiation during surgery — referred to as intraoperative radiation — to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins ...
Targeted radiation therapy might be a safer way to treat a potentially dangerous heart rate problem, a new study says. Radiation therapy treated ventricular tachycardia as well as a standard but ...
While targeted radiation can be an effective treatment for brain tumors, subsequent potential necrosis of the treated areas ...
Radiation therapy advancements, including SBRT and proton therapy, have improved precision and reduced side effects for GI cancer patients, enhancing their quality of life. Personalized treatment ...
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback